Pharma News

Revenue for Cetirizine hydrochloride is expected to have a CAGR of -32.63% through 2031

Cetirizine hydrochloride is a Small Molecule owned by UCB, and is involved in 5 clinical trials, which were completed.

Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H1-receptors. Cetirizine competes with histamine for binding at H1-receptor sites on the effector cell surface and occupies the histamine receptor sites, resulting in suppression of histaminic edema, flare and pruritus.

The revenue for Cetirizine hydrochloride is expected to reach a total of $312m through 2031. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cetirizine hydrochloride NPV Report.

Cetirizine hydrochloride is currently owned by UCB. GSK is the other company associated in development or marketing of Cetirizine hydrochloride.

Cetirizine hydrochloride Overview

Cetirizine hydrochloride (Zyrtec, Zirtec, Zyrtec P, Benaday, ZyrtecSet, Benadryl, Reactine) is an antihistamine and an anti-allergic agent. It is formulated as tablets, film coated tablets, chewable tablets, capsules, dry syrup, drops and solution for oral route of administration. It is indicated for the relief of symptoms associated with seasonal allergic rhinitis due to allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and older, symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes. It is also indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in adults and children 6 months of age and older. It is further indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It is further indicated for the treatment of nasal congestion.

UCB Overview

UCB is a biopharmaceutical company that is engaged in the discovery and development of novel medicines and solutions for the treatment of various severe diseases. It strives to develop products for the treatment of neurology and immunology related conditions. The company’s marketed products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, psoriatic arthritis, non-radiographic axial spondyloarthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; Evenity for osteoporosis, and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Brussels-Capital Region, Belgium.

The company reported revenues of (Euro) EUR5,777 million for the fiscal year ended December 2021 (FY2021), an increase of 8% over FY2020. In FY2021, the company’s operating margin was 22.2%, compared to an operating margin of 18.2% in FY2020. In FY2021, the company recorded a net margin of 18.3%, compared to a net margin of 13.7% in FY2020.

Quick View – Cetirizine hydrochloride

Report Segments
Drug Name
Administration Pathway
Therapeutic Areas
  • Dermatology
  • Immunology
  • Ophthalmology
  • Respiratory
Key Companies
Highest Development Stage

Source link
#Revenue #Cetirizine #hydrochloride #expected #CAGR

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *